C. Decker

发表

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Jinglan Zhou, P. Negulescu, P. Grootenhuis, 2009, Proceedings of the National Academy of Sciences.

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

A. Kwong, B. G. Rao, P. Chaturvedi, 2006, Antimicrobial Agents and Chemotherapy.

(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Act

P. Charifson, C. Decker, U. Germann, 2007, Journal of Pharmacology and Experimental Therapeutics.

Efficient Screening of Cytochrome P450 BM3 Mutants for Their Metabolic Activity and Diversity toward a Wide Set of Drug-Like Molecules in Chemical Space

P. Grootenhuis, N. Vermeulen, C. Decker, 2011, Drug Metabolism and Disposition.

Chapter 6 Efficient screening of P 450 BM 3 mutants to metabolize drug-like molecules

P. Grootenhuis, J. V. Leeuwen, C. Decker, 2010 .

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

P. Negulescu, P. Grootenhuis, F. van Goor, 2009, Proceedings of the National Academy of Sciences.

Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor

C. Decker, C. Moody, Christine Memmott, 2002, Journal of Pharmacology and Experimental Therapeutics.

Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.

Sabine Hadida, C. Decker, A. Termin, 2014, Bioorganic & medicinal chemistry letters.

Chemical and enzymatic oxidation of benzimidazoline-2-thiones: a dichotomy in the mechanism of peroxidase inhibition.

C. Decker, D. Doerge, R. S. Takazawa, 1993, Biochemistry.

Covalent binding of 14C- and 35S-labeled thiocarbamides in rat hepatic microsomes.

C. Decker, D. Doerge, 1992, Biochemical pharmacology.

Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts.

S. Wrighton, W. Trager, A. Rettie, 1987, Archives of biochemistry and biophysics.

Prediction of pharmacokinetic properties using experimental approaches during early drug discovery.

C. Decker, P R Chaturvedi, C J Decker, 2001, Current opinion in chemical biology.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

P. Negulescu, P. Grootenhuis, J. Wine, 2011, Proceedings of the National Academy of Sciences.

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.

C. Decker, S. Raybuck, R. Tung, 1998, Journal of pharmaceutical sciences.

Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450.

T. Baillie, D. Maltby, C. Decker, 1989, Biochemistry.

Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.

Jinglan Zhou, P. Negulescu, P. Grootenhuis, 2014, Journal of medicinal chemistry.

Rat hepatic microsomal metabolism of ethylenethiourea. Contributions of the flavin-containing monooxygenase and cytochrome P-450 isozymes.

C. Decker, D. Doerge, 1991, Chemical research in toxicology.

Inhibition of peroxidase-catalyzed reactions by arylamines: mechanism for the anti-thyroid action of sulfamethazine.

C. Decker, D. Doerge, 1994, Chemical Research in Toxicology.

The role of biotransformation in the estrogenicity of xenobiotics

P. Grootenhuis, C. Decker, J. Saunders, 2010 .